The vagaries of prostate cancer screening

Journal of Medical Screening

Volumn 11, Issue 4, 2004, Pages 163-164

  Law, Malcolm ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD LEVEL; BLOOD SAMPLING; CANCER MORTALITY; CANCER SCREENING; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EDITORIAL; FOLLOW UP; GENERAL PRACTITIONER; HEALTH SERVICE; HISTOPATHOLOGY; HUMAN; PATIENT EDUCATION; PATIENT MONITORING; PROSTATE CANCER; RESPONSIBILITY; RISK BENEFIT ANALYSIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYMPTOM; TUMOR BIOPSY; VALIDATION PROCESS;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 10844264477     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/0969141042467421     Document Type: Editorial

References (14)

1. Parkes C, Wald NJ, Murphy P, et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. I 1995;311:340-43.
2. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
3. Woolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med 1995;23:1401-05.
4. Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344:1373-77.
5. Law M. Screening without evidence of efficacy. BMJ 2004;328:301-02.
6. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectamy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 2000;92:1582-92.
7. Russo A, Autelitana M, Bellini A, Bisanti L. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. J Med Screen 2002;9:179-80.
8. Chapple A, Ziebland S, Shepperd S, Miller R, Herxheimer S, McPherson A. Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative testing. BMJ 2002;325:737-39.
9. Gattellari M, Ward JE. Will men attribute fault to their GP for harms arising from controversial screening tests? An Australian study using scenarios about PSA testing. J Med Screen 2004;11:TBA
10. Stamey TA. Preoperative serum prostate-specific antigen (PSA) below 10 μg/L predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. Clin Chem 2001;47:631-34.
11. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
12. D'Amico AV, Chen M-H, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
13. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002;325:740-43.
14. Auvinen A, Rietbergen JBW, Denis LJ, Schröder FH, Prorok PC for the International Prostate Cancer Screening Trial Evaluation Group. Prospective evaluation plan for randomised trials of prostate cancer screening. J Med Screen 1996;3:97-104.